Pure Global AI
NCT06159283Not yet recruiting

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment: a Multicenter Randomized Controlled Trial
Jaehoon KoPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
COVID-19
Drug/Device/Intervention
Immunoglobulins
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jaehoon Ko
Funder
Samsung Medical Center
Timeline & enrollment
Phase
Phase 2
Start date
Jan 01, 2024
End date
Dec 31, 2025
Enrollment
58 participants
Primary outcome

Evaluation of clinical effectiveness

Summary

This is a multicenter, randomized controlled trial aiming to investigate the efficacy of
 intravenous immunoglobulin (IVIG) replacement therapy under the hypothesis that
 immunoglobulin replacement would have therapeutic effects on persistent COVID-19 in patients
 with B-cell impairment.

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteViral infection, unspecifiedRift Valley fever
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06159283
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06159283 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jaehoon Ko and is currently Not yet recruiting. The study focuses on COVID-19. Target enrollment is 58 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.